Loading company
Apyx Medical Corp
APYX · Nasdaq · ·
Next earnings: November 5, 2026
$2.61+4.0%Sep 29 close
- 1M
- -15.4%
- 6M
- -27.2%
- 1Y
- +21.7%
- 5Y
- -81.2%
APYX · Nasdaq · ·
Next earnings: November 5, 2026
$2.61+4.0%Sep 29 close
Apyx Medical Corp is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $13.9M | $11.4M | +22.08% |
| Profit | -$3.2M | -$3.8M | +14.16% |
| Profit per share | -$0.19 | -$0.03 | -533.33% |
| Free Cash Flow | -$3.6M | -$1.5M | -137.38% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Body Contouring System™ : AYON is a groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates advanced fat removal technologies, Renuvion’s tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. With advanced features like LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. Backed by Apyx Medical’s expertise and evidence-based design, AYON delivers consistent, reliable performance and an unmatched return on investment. As the first of its kind, AYON is revolutionizing body contouring and shaping the future of aesthetic surgery.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Apyx Medical Corp’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Apyx Medical Corp has no earnings call transcript available.